1KPA Stock Overview
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Protara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.44 |
| 52 Week High | US$4.42 |
| 52 Week Low | US$1.13 |
| Beta | 1.79 |
| 11 Month Change | 34.81% |
| 3 Month Change | 34.81% |
| 1 Year Change | 115.93% |
| 33 Year Change | -59.67% |
| 5 Year Change | n/a |
| Change since IPO | -90.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1KPA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 16.2% | 0.8% | 0.8% |
| 1Y | 115.9% | -18.3% | 8.6% |
Return vs Industry: 1KPA exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 1KPA exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 1KPA volatility | |
|---|---|
| 1KPA Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1KPA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1KPA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 27 | Jesse Shefferman | www.protaratx.com |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition.
Protara Therapeutics, Inc. Fundamentals Summary
| 1KPA fundamental statistics | |
|---|---|
| Market cap | €51.20m |
| Earnings (TTM) | -€40.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs 1KPA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1KPA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.05m |
| Earnings | -US$42.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1KPA perform over the long term?
See historical performance and comparison